Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 166

1.

Exosomes promote pre-metastatic niche formation in ovarian cancer.

Feng W, Dean DC, Hornicek FJ, Shi H, Duan Z.

Mol Cancer. 2019 Aug 13;18(1):124. doi: 10.1186/s12943-019-1049-4. Review.

2.

Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway.

Shen S, Dean DC, Yu Z, Duan Z.

Hepatol Res. 2019 Apr 22. doi: 10.1111/hepr.13353. [Epub ahead of print] Review.

PMID:
31009153
3.

miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.

Li D, Wang X, Yang M, Kan Q, Duan Z.

Exp Cell Res. 2019 Jul 1;380(1):20-28. doi: 10.1016/j.yexcr.2019.03.025. Epub 2019 Mar 20.

PMID:
30904483
4.

Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer.

Chen J, Yu Y, Li H, Hu Q, Chen X, He Y, Xue C, Ren F, Ren Z, Li J, Liu L, Duan Z, Cui G, Sun R.

Mol Cancer. 2019 Mar 2;18(1):33. doi: 10.1186/s12943-019-0947-9.

5.

Advances in immune checkpoint inhibitors for bone sarcoma therapy.

Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z.

J Bone Oncol. 2019 Jan 29;15:100221. doi: 10.1016/j.jbo.2019.100221. eCollection 2019 Apr. Review.

6.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

FASEB J. 2019 May;33(5):5990-6000. doi: 10.1096/fj.201801789RR. Epub 2019 Feb 6.

PMID:
30726104
7.

Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.

Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z.

Int J Cancer. 2019 Aug 15;145(4):979-993. doi: 10.1002/ijc.32180. Epub 2019 Feb 15.

PMID:
30719715
8.

Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.

Tang F, Min L, Seebacher NA, Li X, Zhou Y, Hornicek FJ, Wei Y, Tu C, Duan Z.

J Orthop Res. 2019 Mar;37(3):789-798. doi: 10.1002/jor.24227. Epub 2019 Feb 12.

PMID:
30667081
9.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.

Ma H, Seebacher NA, Hornicek FJ, Duan Z.

EBioMedicine. 2019 Jan;39:182-193. doi: 10.1016/j.ebiom.2018.12.022. Epub 2018 Dec 20.

10.

Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.

Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z.

J Orthop Res. 2019 Feb;37(2):510-521. doi: 10.1002/jor.24189. Epub 2019 Jan 3.

PMID:
30488489
11.

RNA sequencing (RNA-Seq) and its application in ovarian cancer.

Wang J, Dean DC, Hornicek FJ, Shi H, Duan Z.

Gynecol Oncol. 2019 Jan;152(1):194-201. doi: 10.1016/j.ygyno.2018.10.002. Epub 2018 Oct 5. Review.

PMID:
30297273
12.

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.

Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z.

Cancer Lett. 2018 Dec 28;439:66-77. doi: 10.1016/j.canlet.2018.09.012. Epub 2018 Sep 14. Review.

PMID:
30223067
13.

From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.

Dean DC, Shen S, Hornicek FJ, Duan Z.

Cancer Metastasis Rev. 2018 Dec;37(4):719-731. doi: 10.1007/s10555-018-9763-8. Review.

PMID:
30167827
14.

MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Chen J, Yu Y, Chen X, He Y, Hu Q, Li H, Han Q, Ren F, Li J, Li C, Bao J, Ren Z, Duan Z, Cui G, Sun R.

Cell Prolif. 2018 Dec;51(6):e12510. doi: 10.1111/cpr.12510. Epub 2018 Aug 13.

PMID:
30105813
15.

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2018 Aug 9;8(1):12107. doi: 10.1038/s41598-018-30644-x.

16.

Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.

Wang J, Garbutt C, Ma H, Gao P, Hornicek FJ, Kan Q, Shi H, Duan Z.

Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.

PMID:
29699801
17.

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Liu T, Yan Z, Liu Y, Choy E, Hornicek FJ, Mankin H, Duan Z.

Cell Physiol Biochem. 2018;46(3):1218-1230. doi: 10.1159/000489072. Epub 2018 Apr 16.

18.

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.

Li X, Seebacher NA, Garbutt C, Ma H, Gao P, Xiao T, Hornicek FJ, Duan Z.

Cell Death Dis. 2018 May 1;9(5):446. doi: 10.1038/s41419-018-0474-4.

19.

Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma.

Ma H, Li X, Wang J, Hornicek FJ, Garbutt CC, Chang X, Duan Z.

Oncology. 2018;95(1):52-60. doi: 10.1159/000487437. Epub 2018 Apr 4.

20.

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.

Chen H, Shen J, Choy E, Hornicek FJ, Shan A, Duan Z.

Oncotarget. 2017 Nov 28;9(17):13154-13166. doi: 10.18632/oncotarget.22743. eCollection 2018 Mar 2.

Supplemental Content

Loading ...
Support Center